Results 11 to 20 of about 132,229 (258)

Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report

Journal of Medical Case Reports, 2019
Background Primary sarcoma of the breast is rare. Surgery has been the only curative treatment available. Recently, neoadjuvant chemotherapy including anthracycline/ifosfamide has been reported effective for patients with high-risk sarcomas in a ...
Chieko Miyazaki, Mikio Shiozawa, Rintaro Koike, Kasumi Ogihara, Yumiko Sasaki, Satomi Shiba, Saki Nishida, Masako Sakuragi, Hirofumi Mizunuma, Takashi Fujita, Noriyoshi Fukushima, Alan K. Lefor, Joji Kitayama, Naohiro Sata   +13 more
doaj   +1 more source

CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2011
BACKGROUND: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell ...
Zhien Feng, Wei Guo, Chenping Zhang, Qin Xu, Ping Zhang, Jian Sun, Hanguang Zhu, Zhonghe Wang, Jiang Li, Lizhen Wang, Bingshun Wang, Guoxin Ren, Tong Ji, Wenyong Tu, Xihu Yang, Weiliu Qiu, Li Mao, Zhiyuan Zhang, Wantao Chen   +18 more
doaj   +1 more source

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

PLoS ONE, 2022
Background Diffuse malignant peritoneal mesothelioma (DMPM) is a rare variant of malignant mesothelioma, representing 10–15% of malignant mesothelioma cases.
Xiao Wang, Sharyn Katz, John Miura, Giorgos Karakousis, Leonid Roshkovan, Suzanne Walker, Sally McNulty, Christine Ciunci, Keith Cengel, Corey J. Langer, Melina E. Marmarelis   +10 more
doaj   +2 more sources

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Scientific Reports, 2022
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC).
Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Wu-Chou Su   +16 more
doaj   +1 more source

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma

Radiation Oncology, 2019
Purpose Neoadjuvant chemoradiation or chemotherapy has improved the treatment efficacy of patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Qiancheng Hu, Dan Wang, Ye Chen, Xiaofen Li, Peng Cao, Dan Cao   +5 more
doaj   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade

Journal of Immunology Research, 2022
Although tumor immune microenvironment plays an important role in antitumor therapy, few studies explored the gene signatures associated with the tumor immune microenvironment of bladder cancer after neoadjuvant chemotherapy.
Hao Luo, Gao-Lei Liu, Dan Jian, Dan-Dan Liang, Xue-Mei Li, Li Zhong, Bo Yang, Jun Jiang, Dong Wang, Meng-Xia Li, Wei-Hua Lan, Nan Dai   +11 more
doaj   +1 more source

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

Menopause Review, 2022
Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian ...
Chrysoula Margioula-Siarkou, Stamatios Petousis, Alexios Papanikolaou, Giuseppe Gullo, Georgia Margioula-Siarkou, Antonio Simone Laganà, Konstantinos Dinas, Frederic Guyon   +7 more
doaj   +1 more source

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer

Current Oncology
The utility of neoadjuvant chemotherapy is expanding in the treatment of breast cancer. Although individual trials have shown comparable survival between patients receiving neoadjuvant and adjuvant chemotherapy, large-scale data analyses for outcomes in ...
Farhad Ghasemi, Muriel Brackstone
doaj   +1 more source